GLP-2-T 30MG
$105.00
Tirzepatide is a synthetic dual receptor agonist peptide that binds both the GLP-1 and the GIP receptor.
It is a 39-amino-acid sequence carrying a C20 fatty diacid moiety, a modification that extends its half-life through albumin binding. Engaging two incretin receptors with one molecule allows researchers to study the interaction between the two signaling pathways directly.
Researchers study Tirzepatide in:
- GLP-1 and GIP receptor binding and activation assays
- cAMP and downstream signaling studies
- Incretin pathway research
- Comparative studies against single-receptor agonists
- Peptide stability and formulation research
For research use only. Not for human or veterinary use.
MECHANISM
How Does It Work?
Tirzepatide activates two receptors involved in appetite regulation, fat metabolism, and blood sugar control.
| GLP-1 Receptor | GIP Receptor |
|---|---|
| Signals fullness, slows digestion, stimulates insulin release, and helps reduce blood sugar spikes after meals. | Enhances insulin response and helps regulate how the body stores and uses fat. |
Research suggests the interaction between GLP-1 and GIP receptors creates a stronger combined metabolic response than single-receptor compounds alone.
PHYSICAL PROPERTIES
| Property | Details |
|---|---|
| Form | Lyophilized powder |
| Color | White to off-white |
| Molecular Weight | 4,813.5 g/mol |
| Storage | Refrigerated 36–46°F (2–8°C), avoid freeze-thaw cycles |
| Reconstitution | Bacteriostatic or sterile water recommended |
| Stability | 24 months lyophilized, use within 30 days after reconstitution |
POTENTIAL SIDE EFFECTS IN RESEARCH
The following effects have been observed in preclinical and clinical studies. Researchers should monitor subjects carefully and document all observations.
| Nausea & Digestive Discomfort | Increased Heart Rate |
|---|---|
| The most commonly reported observation. Usually mild and tends to improve as research protocols continue. | Mild increases in resting heart rate have been observed in some subjects. Generally well-tolerated. |
| Injection Site Irritation | Low Blood Sugar |
|---|---|
| Minor redness or swelling at the injection site. Typically temporary and resolves without intervention. | Rare, but observed particularly when combined with other glucose-lowering compounds. |
| Reduced Appetite | Slower Digestion |
|---|---|
| A significant decrease in appetite is consistently observed in research models and is considered an expected effect. | Food moves through the digestive system more slowly due to GLP-1 receptor activation. |
DISCLAIMER
This product is exclusively for laboratory research. Not approved for human or veterinary use.
All products sold by Ikon Peptides are intended exclusively for in-vitro laboratory research. Not approved for human consumption or veterinary use. These statements have not been evaluated by the FDA.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Related products
